Escitalopram Canon - instructions for use, doses, side effects, contraindications, price, where to buy

Indications

◊ Recommendations of the Russian Ministry of Health

F32 Depressive episode

F33 Recurrent depressive disorder

F40.0 Agoraphobia

F41.0 Panic disorder (episodic paroxysmal anxiety)

◊ FDA recommendations

Major depressive disorder (adults and children over 12 years of age)
GTR

◊ Recommendations from UK Medicines and Healthcare Products Regulatory Agency

Major depressive episode
Panic disorder with/without agoraphobia
Social phobia
GTR
OCD

◊ Using Off-label

Vasomotor symptoms during menopause
Insomnia
Dysmorphophobia
Bulimia [5].

Mechanism of action and pharmacokinetics

Escitalopram is the S-isomer of citalopram. Selectively inhibits the reuptake of serotonin, increasing the concentration of this neurotransmitter in the synaptic cleft. Escitalopram, like other antidepressants from the SSRI group, practically does not bind to dopamine (D1 and D2) receptors, α-adrenergic and m-cholinergic receptors, as well as benzodiazepine and opioid receptors [4]. Long-term use of escitalopram leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors.

Bioavailability – 80%.
Half-life 27-32 hours
Stable concentration in the blood is maintained for one week
Metabolized by CYP3A4, CYP2C19; inhibits CYP2D6

Drug interactions Escitalopram

It does not potentiate the effect of alcohol on the central nervous system, but drinking alcohol during treatment with escitalopram is not recommended. Concomitant use with MAO inhibitors is contraindicated. When used simultaneously with acetylsalicylic acid, other NSAIDs and other drugs with antiplatelet effects, the risk of developing gastrointestinal bleeding increases. With the simultaneous use of selective serotonin reuptake inhibitors with sumatriptan, isolated cases of weakness, hyperreflexia and incoordination have been described; when prescribing such a combination, the patient should be under medical supervision. Combined use with ketoconazole may lead to a decrease in the concentration of the latter in the blood serum.

Treatment regimen

◊ Dosage and dose selection

Optimal dose for treating depression, OCD and GAD: 10-20 mg/day
Start with 10 mg/day, increase to 20 mg if necessary
Take once daily, morning or evening
10 mg escitalopram is comparable to 40 mg citalopram, but without side effects
A dose of 30-40 mg is suitable for some patients [1]
To relieve vasomotor symptoms during menopause, 10 mg/day is sufficient, but if ineffective within 4 weeks, the dose may be increased to 20 mg/day
If anxiety, insomnia, agitation, or akathisia occur at the beginning of treatment or after interruption of treatment, the possibility of bipolar disorder should be considered and switched to a mood stabilizer or an atypical antipsychotic

◊ How quickly it works

Begins to act after 2-4 weeks
If there is no effect after 6-8 weeks, you need to increase the dose or switch to another drug
To prevent relapse, it can be taken for many years.

◊ Expected result

Complete remission.
After the symptoms of depression disappear, you should continue taking it for 1 year if this was the treatment of the first episode. If this is to treat a recurrent episode, treatment can be extended indefinitely.
Use in the treatment of anxiety and chronic pain may be indefinite.

◊ If it doesn't work

Change the dose, switch to another medicine or add an auxiliary drug;
Connect psychotherapy;
Review the diagnosis by identifying comorbid conditions;
In patients with undiagnosed bipolar affective disorder, the effectiveness of treatment may be low, in which case it is necessary to switch to a mood stabilizer [1].
In the acute phase of severe depressive disorder, which is accompanied by psychotic or catatonic symptoms, as well as in patients with current suicidal ideation, electroconvulsive therapy should be considered [7].

◊ How to stop taking it

It is usually not necessary to reduce gradually, but to be sure to avoid withdrawal symptoms, you can reduce it gradually. Gradual reduction scheme: dose reduced by 50% - 3 days, again reduced by 50% - 3 days, complete cessation. If withdrawal symptoms appear, increase the dose, wait for withdrawal symptoms to subside, and continue decreasing [1].

◊ Treatment combinations

For insomnia: trazadone
For fatigue, drowsiness, loss of concentration: modafinil [3].
Combinations with other antidepressants may activate bipolar disorder and suicidal ideation
For bipolar depression, psychotic depression, treatment-resistant depression, treatment-resistant anxiety disorder: mood stabilizers, atypical antipsychotics
For anxiety disorder: gabapentin, tiagabine

The effectiveness of the drug escitalopram (Cipralex) in the treatment of panic attacks

Escitalopram (Cipralex) is a highly selective serotonin reuptake inhibitor (SSRI) with proven effectiveness against panic disorders. Due to the selectivity of their action, antidepressants of the SSRI group have a significantly lower number of side effects and the degree of their severity in comparison with drugs of the previous generation - tricyclic antidepressants. The antidepressant effect of escitalopram has been demonstrated in clinical trials, including placebo-controlled ones, mainly in patients with depressive disorders.

Table 1. Patient population

Table 2. Previous diagnoses

Table 3. Groups of drugs used as therapy

Table 4. Main complaints during an attack of PA

Table 5. First Panic Score

Table 6. What, according to the patient, is associated with the development of the disease

Table 7. Characteristics of attacks

Table 8. Dynamics of attacks

Rice. 1. Weekly self-assessment according to VAS for 10 weeks

Table 9. Dynamics of test indicators over 10 weeks

Table 10. Subjective assessment of escitalopram therapy in patients with PsA

Escitalopram is the S-enantiomer of the SSRI citalopram, a racemic compound consisting of two isomers (S- and R-). It has been established that the ability of the S-isomer to inhibit serotonin reuptake is more than 100 times higher than that of the R-isomer. S-citalopram was isolated as an independent drug, which is superior to citalopram in the speed of development of the clinical effect and the degree of its severity.

Thus, in previous studies, using escitalopram at a fixed dose of 10 mg/day, the same improvement in key parameters of antidepressant efficacy was observed as when using 40 mg citalopram. The early and persistent antidepressant effect of escitalopram is achieved using doses in the range of 10–20 mg/day. with exceptionally good tolerability [11]. According to multicenter studies conducted in the United States, escitalopram was well tolerated in 76% of cases, regardless of dose. Discontinuation of escitalopram due to side effects was recorded in 4.2% of those taking the drug at a dose of 10 mg/day. and in 10.4% - at a dose of 20 mg/day. [16]. The severity of adverse events that occurred during therapy does not exceed 2 points on the scale of side effects of therapy (UKU), which indicates the absence of a significant impact on the patient’s condition and functioning. The dynamics of adverse events are regressive in nature, i.e., by the end of the 2nd week of treatment, most manifestations are mild and lose both objective and subjective significance [3].

Panic attacks (PA) are the most severe form of anxiety disorders, leading to severe maladjustment [14], having a chronic course with exacerbations and remissions [4]. PAs are discrete periods in which there is a sudden onset of intense anxiety, fear or terror, often associated with a feeling of impending doom. These attacks are characterized by symptoms such as shortness of breath, throbbing, chest pain or discomfort, a feeling of suffocation, and fear of “going crazy” or “losing control” [5]. Diagnostic criteria for a panic attack (PA) are paroxysmalness, polysystemic vegetative symptoms, the presence of emotional disorders, the severity of which can range from “a feeling of discomfort” to “panic.”

Purpose of the study

The effectiveness and tolerability of a 10-week course of escitalopram (Lundbeck) at a dose of 5–10 mg/day were assessed. in the treatment of panic disorders according to the dynamics of clinical characteristics and psychometric indicators, as well as identifying predictors of therapy effectiveness. The main assessment of effectiveness was made by the frequency of panic attacks in the 10th week of treatment compared with baseline indicators (before the start of treatment) and the effect of the drug on comorbid conditions. The effectiveness of escitalopram was verified by a statistically significant reduction in panic attacks, a decrease in the level of anxiety, and depression.

Research material

Forty outpatients fulfilling DSM-IV (1994) and ICD-10 (1995) criteria [13, 17] for panic disorder with or without agoraphobia. All subjects had typical PAs – the typicality index was 0.68 [3]. Among the examined patients, there were 27 (67.5%) women and 13 (32.5%) men. The average age of patients in the whole group at the time of treatment was 35.9 ± 9.1 years (from 24 to 61 years). The average age of onset of PA was 33.8 ± 8.1 years (from 23 to 57 years), with 33.3% being within the age limit of 25–35 years, 33.3% within the age limit of 35–40 years, and 14 .8% – within 30–35 years. That is, all the examined persons were of active, working age. The average duration of the disease in the group was 1.1 ± 1.1 years (from 1 month to 4 years). The patient population is presented in Table 1.

Among the examined patients, 29.6% suffered from agoraphobia. These patients were unable to travel on the subway on their own or drive their own car (only when accompanied by loved ones). 25.9% had restrictive behavior, which included poor tolerance of hypermarkets, markets, and other public places that provoke attacks of PA due to “flashing before the eyes of people and a lot of goods.” Among the observed patients, 11 are car owners, but due to attacks of PA they were forced to give up driving a car independently. During therapy, patients began to drive again without any subjective difficulties, which indicates good tolerability of escitalopram against the backdrop of a pronounced effect of increasing concentration.

Professional representation

In the groups of patients there were representatives of different professions, among them 81.5% had a permanent job (manager, head of construction operation, company administrator, doctor, deputy general director of the enterprise, leading specialist in regional supplies, accountant, director of the company, economist, bank employee, businessman, pharmacist, supermarket salesman, curtain designer, personal chef) and 18.5% did not work (housewife, pensioner). Only one patient left work due to the onset of her illness, the rest - due to somatic diseases or age. 51.8% had higher education, 48.2% had specialized secondary education. As can be seen from the list of professions, the vast majority of the patients studied occupy leadership and responsible positions that require maximum internal stress.

It turned out that more than half of the patients had a combination of clinical syndromes: autonomic dysfunction, algic manifestations, motivational and insomnia disorders.

Headaches were observed in 30% of cases. The characteristics of headaches in patients with PA had some signs of tension headaches (localization in the fronto-parieto-temporal region, of a pressing nature, the average intensity on the VAS reached 4-5 points) and differed from the latter in the accompanying symptoms: a feeling of “heaviness in the head”, “ deterioration of hearing”, the feeling that “one can hear the heartbeat”, “something is tense in the head.” Since headaches occurred only in association with other symptoms, these characteristics may indicate that headache was part of a psycho-vegetative complex.

The majority of patients (63%) who sought help had previous diagnoses that either reflected failure in the somatic sphere or did not have a clear nosological focus; 37.5% had no diagnosis at all and only 15% had a corresponding diagnosis of PA (Table 2). The data obtained indicate that panic disorder is underdiagnosed in general somatic practice.

Previous treatment

All patients unsuccessfully or insufficiently effectively (the effect lasted for several days or, less often, 1 month) took a number of drugs without receiving the proper therapeutic effect.

Study design and methods

The patients were examined during the 2nd, 4th, 6th and 10th weeks of continuous therapy with escitalopram. The following methods were used to assess the status of patients:

clinical and neurological examination according to the survey protocol for patients with PA with assessment of the panic attack typicality index [5];
psychometric testing using the Sheehan Anxiety Scale (Sheehan, 1983), Beck Depression Inventory (Beck, 1961) [2] and quality of life for panic attacks [5], Holmes TM Life Events Scale [18], 10-point visual analogue scale (VAS) for self-assessment of general well-being (where 0 points are the worst, 10 points are the best idea of the state of health) (according to S. Walker, R. Roser, 1993) [2];
subjective assessment of the effectiveness of escitalopram therapy on a 5-point scale (where 0 points is no effect, 5 points is a pronounced effect).

Background indicators

During the initial examination, patients in the study group complained of rapid heartbeat, fluctuations in blood pressure, respiratory distress (hyperventilation, “attacks of suffocation,” “inability to inhale,” “lump in the throat”), tension-type headaches, increased anxiety and internal trembling, fixation on the state of one’s health, decreased performance and a feeling of helplessness, lipothymia (“blackout before the eyes”), sleep disturbance (difficulty falling asleep, early awakenings), “ringing in the ears.” During the attack, each patient had several symptoms. The main symptoms accompanying the attack are presented in Table 4.

At the onset, 9 patients had such severe anxiety and fear of death that they had to call an ambulance or were repeatedly hospitalized. The assessment of the “first panic” is presented in Table 5.

Neurological status

In the vast majority of patients, the following features were revealed in their neurological status: revival of tendon reflexes from the arms and legs with expansion of reflexogenic zones, with unstable pathological hand signs (Rossolimo, Hoffman rivers), dissociation of reflexes along the axis (more vividly from the legs than from hands), Khvostek's sign of I–II degree, wetness of the hands, nystagmus in the extreme abductions, slight asymmetry (smoothness) of the nasolabial folds.

An analysis of patients’ opinions regarding the provoking factor in the development of the disease showed that the majority of patients (37.5%) indicated stressful situations at home and/or at work as the main factors that provoked the development of the first attack of PA (Table 6). But it should be noted that there was often a combination of several factors.

Treatment results

The study results showed that out of 40 patients, 33 (82.5%) completed the full 10-week course of escitalopram therapy. Subjectively, the frequency (from 14 to 0–1 attacks per week) and intensity of attacks (from high, with an ambulance call, to complete absence), the duration of one episode (from 24 hours to several minutes), and the number of symptoms in an attack (from 13 to 1) at the end of the course of therapy.

At the initial stage, only a small proportion of patients used therapy correctors: anaprilin, sonopax, alprazolam, fluanxol.

We assessed the effectiveness of therapy based on the qualitative characteristics of the attack and their dynamics, using objective rating scales; we compared the effectiveness in groups of patients who had previously taken and had not taken antidepressants (Table 3). Table 7 presents the qualitative characteristics of the attack.

Noteworthy is the long duration of the attack, which in some patients reached several hours. This circumstance is due to the fact that for the duration of the attack, patients took a combination of events that included the attack itself, a post-attack state in the form of asthenia, anxiety, irritability, headaches, etc., or a series of attacks with short time intervals.

All patients (100%) had daily both full-blown and abortive attacks before starting therapy. In the process of taking the drug, there was the following dynamics: a gradual decrease in attacks and shortening their duration, a decrease in intensity until complete cessation, and an increase in self-control during an attack. The dynamics of attacks are presented in Table 8.

In the background study, all patients (100%) had both spontaneous and situational (100%) attacks of PA. At the end of therapy, spontaneous attacks were not observed in any patient, situational ones persisted in 6 patients and were abortive in nature (a single monosymptomatic attack of low intensity, quickly resolving). In connection with this circumstance, these patients continued taking escitalopram after a 10-week course of therapy.

The drug prescription regimens for those patients (n=33) who completed the full course of therapy were as follows:

The initial dose is 1.25 mg/day. for 10 days, the next 10 days at 2.5 mg/s, the remaining days at 5 mg/day. (n=1);
The initial dose is 2.5 mg/day. for 2–3 weeks, followed by a transition to a dose of 5 mg/day. (n=3);
The initial dose is 5 mg/day. for 3 weeks, followed by a transition to 10 mg/day. (n=2);
The initial dose is 5 mg/day. for 1 week, followed by a transition to 10 mg/day. (n=27).

Most patients used the 4th treatment regimen and the drug was well tolerated. However, when prescribing escitalopram, it should be taken into account that some patients require a specific individual treatment regimen 1, 2 or 3.

The reasons why non-standard treatment regimens were prescribed are as follows. In a patient treated according to regimen 1, after a single dose of 5 mg, severe weakness, dilated pupils, and increased blood pressure were observed - the dose was reduced to 2.5 mg, which also led to increased symptoms of panic. It was decided to further reduce the dose to 1.25 mg, which was well tolerated by the patient. Subsequent dose increases did not cause any side effects. Patients transferred to regimen 2 also turned out to be sensitive to a dose of 5 mg; a dose of 2.5 mg was well tolerated by them. The patient taking the drug according to regimen 3, after a week's course, was unable to switch to a dose of 10 mg; she required a longer adaptation period.

Tolerability of the drug was generally rated by patients as good. Subjectively, within 2 weeks, the following was noted: a decrease in attacks and a decrease in their intensity, an increase in self-assessment of general well-being according to VAS (Fig. 1), improved mood, and normalization of sleep. Objectively, all test indicators reliably changed for the better (Table 9).

Subjective assessment data (on a 5-point scale) of escitalopram therapy by patients who completed a 10-week course of treatment are presented in Table 10. Most patients rated the drug at 5 points. The average sum score was 4.57.

Tolerability of the drug included side effects, paradoxical reactions, and drug refusal. On days 1–3, almost all patients reported side effects of varying severity: dizziness, “drowsiness,” decreased concentration, and increased anxiety. Paradoxical reactions developed, as a rule, during the first week (on days 3-5-7 of therapy at a dose of 5 mg/day or when switching to a dose of 10 mg/day): severe weakness, rise in blood pressure, sharp worsening of all symptoms of PA, sleep disturbance (insomnia, drowsiness), leg cramps. This was the reason for refusal of escitalopram therapy in 7 (17.5%) patients (5 women, 2 men). The drug was well tolerated by most patients in the following days.

Conclusion

The study showed the high effectiveness of Escitalopram in the treatment of panic disorder over a 10-week course. Patients who completed the course of treatment subjectively highly rated both the effectiveness of the drug and its tolerability.

The anti-panic effect appears in the 2-3rd week of therapy; first of all, full-blown attacks undergo regression. The undeniable advantage of Escitalopram is its effectiveness against concomitant agoraphobic and depressive disorders. The dynamics of the reverse development of depressive symptoms and symptoms of agoraphobia correspond to the regression of panic attacks. Symptoms of agoraphobia have proven to be the most resistant to treatment. In treated patients who retained PA at the end of the treatment course, only situational PA (a marker of agoraphobia) was observed. In the presence of severe agoraphobia and severe panic disorder, longer courses of treatment may be recommended - from 3 to 5 months.

Thus, escitalopram can be recommended as monotherapy or a basic drug in polytherapy for the treatment of panic disorder.

Special patient groups

◊ Patients with kidney problems

Use caution if the patient has severe kidney disease [1].

◊ Patients with liver disease

The recommended dose is 10 mg/day [1].

◊ Patients with heart disease

There are no systematic data on the use of escitalopram in people with pathology of the cardiovascular system. Supposedly safe. Useful in recovery after a heart attack [1].

◊ Elderly patients

For elderly patients, a dose of 10 mg is recommended [1].

◊ Children and teenagers

Recommended for the treatment of depression aged 12-17 years
It is necessary to regularly and personally check the patient's condition, especially in the first weeks of treatment.
Use with caution due to the risk of undiagnosed bipolar disorder and suicidality.
Inform adults about the risks.

◊ Pregnant women

There have been no adequate studies in pregnant women [1].
Not recommended for pregnant women, especially in the first trimester
All risks should be weighed and compared
Bleeding can be expected during childbirth

◊ Breastfeeding

The medicine passes into breast milk.
If the infant shows signs of irritation or sedation, discontinue feeding or escitalopram
However, treatment after childbirth may be necessary, so the risks should be weighed.

Escitalopram

Use with MAO inhibitors

Escitalopram should not be co-administered with MAO inhibitors due to the risk of developing serotonin syndrome. Escitalopram can be prescribed 14 days after stopping treatment with irreversible MAO inhibitors and at least 1 day after stopping treatment with reversible MAO type A inhibitors (moclobemide).

At least 7 days must pass after stopping escitalopram before treatment with non-selective MAO inhibitors can be started. Use of the drug in children and adolescents under 18 years of age Antidepressants are contraindicated in children and adolescents under 18 years of age due to an increased risk of suicidal behavior (suicide attempts and suicidal thoughts), hostility (with a predominance of aggressive behavior, a tendency to confrontation and irritation) .

Paradoxical anxiety

When using drugs belonging to the therapeutic group of SSRIs, including escitalopram, it should be taken into account that some patients with panic disorders may experience increased anxiety when starting treatment with SSRIs. This paradoxical reaction usually disappears within the first two weeks of treatment. To reduce the likelihood of an anxiogenic effect, it is recommended to use low initial doses.

Epileptic seizures

Escitalopram should be discontinued if the patient experiences an epileptic seizure for the first time or if seizures become more frequent (in patients with a history of epilepsy).

Patients with unstable epilepsy should avoid taking SSRIs, and patients with controlled epilepsy should be closely monitored.

Mania

Escitalopram is recommended to be prescribed with caution to patients with a history of mania or hypomania. If a manic state develops, escitalopram should be discontinued.

Diabetes

In patients with diabetes mellitus, treatment with escitalopram may alter plasma glucose levels. Therefore, dose adjustments of insulin and/or oral hypoglycemic drugs may be required.

Suicide/suicidal ideation or clinical worsening of depression

Careful monitoring of patients taking antidepressants is necessary, especially at the beginning of therapy, due to the possibility of clinical worsening and/or the emergence of suicidal thoughts and behavior. Clinical experience shows that increased risk of suicide tends to occur in the early stages of recovery.

Other psychiatric disorders for which escitalopram is prescribed may also be associated with an increased risk of suicidal behavior and behavior. In addition, these diseases may accompany severe depressive disorder. The precautions taken when treating patients with severe depressive disorder also need to be observed when treating patients with other mental disorders.

It is known that patients with a history of suicidal actions and symptoms, or those who exhibited suicidal ideation before treatment, are at greater risk of suicidal ideation or attempts and should therefore be closely monitored during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressants in adult patients with mental disorders showed an increased risk of suicidal behavior with antidepressants compared with placebo in patients less than 25 years of age. Careful monitoring of patients, particularly those at high risk, should accompany drug therapy, particularly at the beginning of treatment and after dose changes.

Patients and their caregivers should be advised to monitor for any clinical worsening, suicidal behavior or intent, or unusual changes in behavior, and to seek immediate medical attention if such symptoms occur.

Akathisia/psychomotor agitation

SSRI use is associated with the development of akathisia, a condition characterized by unpleasant, debilitating feelings of restlessness and hyperactivity and often accompanied by an inability to sit or stand in one place. This condition most likely occurs during the first few weeks of therapy. Increasing the dose may be harmful to patients who experience these symptoms.

Hyponatremia

While taking the drug, hyponatremia occurs, possibly associated with impaired ADH secretion. Usually disappears when therapy is stopped. Caution must be exercised when prescribing the drug to patients with a history of or at risk of developing hyponatremia: elderly people, patients with liver cirrhosis.

Bleeding

While taking escitalopram, skin hemorrhages (ecchymosis and purpura) may develop. The drug should be used with caution in patients at risk of bleeding, as well as those taking oral coagulants and drugs that affect blood clotting.

Electroconvulsive therapy (ECT)

Caution should be exercised when using the drug concomitantly with electroconvulsive therapy (ECT) due to limited experience with use.

Serotonin syndrome

Patients taking escitalopram and other SSRIs concomitantly with serotonergic drugs may rarely develop serotonin syndrome. The development of this disease may be indicated by a combination of symptoms such as agitation, tremor, myoclonus and hyperthermia. In this situation, you should immediately stop taking the SSRI and the serotonergic drug and begin symptomatic treatment.

Withdrawal symptoms when stopping SSRI therapy

Withdrawal symptoms when stopping treatment are common, especially if treatment is stopped abruptly. In clinical studies, adverse events during treatment discontinuation were observed in approximately 25% of patients receiving escitalopram and in 15% of patients receiving placebo.

The risk of treatment discontinuation may depend on several factors, including duration, dose of treatment, and rate of dose reduction. The most commonly observed reactions include dizziness, sensory disturbances (including paresthesia and electric shock), sleep disturbances (including insomnia and vivid dreams), agitation or restlessness, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhea, rapid heartbeat, emotional instability, irritability and visual disturbances. Typically, these symptoms are mild to moderate in severity, but in some patients they can be severe.

They usually occur within the first few days after stopping treatment, and similar symptoms are much less commonly reported in patients who accidentally miss a dose.

Typically, these symptoms are self-limiting and usually go away within 2 weeks, although some people may experience them for longer (2-3 months or more). It is therefore recommended to gradually reduce the dose of escitalopram after discontinuation of treatment over several weeks or months, depending on the patient's needs.

Cardiac ischemia

Due to limited experience with use, caution should be exercised when using the drug in patients with coronary heart disease (CHD).

Cases of QT prolongation

It was found that escitalopram causes a dose-dependent prolongation of the QT interval. Cases of QT prolongation and ventricular arrhythmias, including torsade de pointes, have been reported during the postmarketing period, predominantly in female patients with hypokalemia or pre-existing QT prolongation or other cardiovascular disease. It is recommended to exercise caution when recommending the drug to patients with severe bradycardia, patients after a recent acute myocardial infarction, or with uncompensated heart failure.

Electrolyte disturbances, such as hypokalemia and hypomagnesemia, increase the risk of dangerous arrhythmias, and these conditions should be corrected before escitalopram is prescribed.

If the drug is prescribed to patients with persistent heart disease, an ECG should be performed before starting treatment.

Escitalopram does not interact pharmacodynamically or pharmacokinetically with alcohol. However, as with other psychotropic drugs, the simultaneous use of escitalopram and alcohol is not recommended.

Side effects and other risks

◊ Mechanism of side effects

Side effects are caused by an increase in serotonin. Most side effects occur immediately after starting treatment and go away over time.

◊ Side effects

Gastroenterological (reduced appetite, nausea, diarrhea, constipation)
Insomnia, sedation, agitation, tremor
Sweating
Urinary dysfunction
Dry mouth
Dangerous side effects: seizures, mania, suicidal ideation
Weight gain: very rare
Sedation: very rare
Sexual dysfunction: yes

◊ What to do about side effects

Wait
Switch to another antidepressant [1].

◊ Long-term use

Safely

◊Addiction

No.

◊ Overdose

There are very few reports of overdose.
Very rare cases of fatal overdoses.
Vomiting, sedation, cardiac arrhythmia, dizziness, tremor.

Escitalopram Canon, 10 mg, film-coated tablets, 28 pcs.

Use with MAO inhibitors Escitalopram should not be administered concomitantly with MAO inhibitors due to the risk of developing serotonin syndrome. Escitalopram can be prescribed 14 days after stopping treatment with irreversible MAO inhibitors and at least 1 day after stopping treatment with reversible MAO type A inhibitors (moclobemide). At least 7 days must pass after stopping escitalopram before treatment with non-selective MAO inhibitors can be started. Use of the drug in children and adolescents under 18 years of age Antidepressants are contraindicated in children and adolescents under 18 years of age due to an increased risk of suicidal behavior (suicide attempts and suicidal thoughts), hostility (with a predominance of aggressive behavior, a tendency to confrontation and irritation) .

In young people under 25 years of age with depression and other mental disorders, antidepressants, compared with placebo, increase the risk of suicidal thoughts and behavior. Therefore, when prescribing the drug and any other antidepressants to young people under 25 years of age, the risk of suicide should be weighed against the benefits of their use. If a decision is made to initiate antidepressant therapy, the patient should be closely monitored for early detection of disturbances or changes in behavior, as well as suicidality. Paradoxical anxiety When using drugs belonging to the therapeutic group of SSRIs, including escitalopram, it should be taken into account that some patients with panic disorders may experience increased anxiety at the beginning of treatment with SSRIs. This paradoxical reaction usually disappears within the first two weeks of treatment. To reduce the likelihood of an anxiogenic effect, it is recommended to use low initial doses. Epileptic seizures Escitalopram should be discontinued if the patient experiences an epileptic seizure for the first time or if seizures become more frequent (in patients with a history of epilepsy). Patients with unstable epilepsy should avoid taking SSRIs, and patients with controlled epilepsy should be closely monitored. Mania Escitalopram is recommended to be prescribed with caution to patients with a history of mania or hypomania. If a manic state develops, escitalopram should be discontinued. Diabetes In patients with diabetes mellitus, treatment with escitalopram may alter plasma glucose levels. Therefore, dose adjustments of insulin and/or oral hypoglycemic drugs may be required. Suicide/suicidal ideation or clinical worsening of depressive conditions Close monitoring of patients taking antidepressants is necessary, especially at the beginning of therapy, due to the possibility of clinical worsening and/or the emergence of suicidal thoughts and behavior. Clinical experience shows that increased risk of suicide tends to occur in the early stages of recovery. Other psychiatric disorders for which escitalopram is prescribed may also be associated with an increased risk of suicidal behavior and behavior. In addition, these diseases may accompany severe depressive disorder. The precautions taken when treating patients with severe depressive disorder also need to be observed when treating patients with other mental disorders. It is known that patients with a history of suicidal actions and symptoms, or those who exhibited suicidal ideation before treatment, are at greater risk of suicidal ideation or attempts and should therefore be closely monitored during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressants in adult patients with mental disorders showed an increased risk of suicidal behavior with antidepressants compared with placebo in patients less than 25 years of age. Careful monitoring of patients, particularly those at high risk, should accompany drug therapy, particularly at the beginning of treatment and after dose changes. Patients and caregivers should be advised to monitor for any clinical worsening, suicidal behavior or intent, or unusual changes in behavior, and to seek immediate medical attention if such symptoms occur. Akathisia/Psychomotor Restlessness SSRIs have been associated with the development of akathisia, a condition characterized by unpleasant, debilitating restlessness and hyperactivity, often accompanied by an inability to sit or stand in one place. This condition most likely occurs during the first few weeks of therapy. Increasing the dose may be harmful to patients who experience these symptoms. Hyponatremia While taking the drug, hyponatremia occurs, possibly associated with impaired secretion of antidiuretic hormone (ADH). Usually disappears when therapy is stopped. Caution must be exercised when prescribing the drug to patients with a history of or at risk of developing hyponatremia: elderly people, patients with liver cirrhosis. Bleeding While taking escitalopram, skin hemorrhages (ecchymosis and purpura) may develop. The drug should be used with caution in patients at risk of bleeding, as well as those taking oral anticoagulants and drugs that affect blood clotting. Electroconvulsive therapy Caution should be exercised during concomitant use of the drug and electroconvulsive therapy (ECT) due to limited experience with use. Serotonin syndrome Patients taking escitalopram and other SSRIs concomitantly with serotonergic drugs may rarely develop serotonin syndrome. The development of this disease may be indicated by a combination of symptoms such as agitation, tremor, myoclonus and hyperthermia. In this situation, you should immediately stop taking the SSRI and the serotonergic drug and begin symptomatic treatment. Withdrawal symptoms after stopping treatment. Withdrawal symptoms when stopping treatment are common, especially if treatment is stopped abruptly. In clinical studies, adverse events during treatment discontinuation were observed in approximately 25% of patients receiving escitalopram and in 15% of patients receiving placebo. The risk of treatment discontinuation may depend on several factors, including duration, dose of treatment, and rate of dose reduction. The most commonly observed reactions include dizziness, sensory disturbances (including paresthesia and electric shock sensations), sleep disturbances (including insomnia and vivid dreams), agitation or restlessness, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhea, rapid heartbeat, emotional instability, irritability and visual disturbances. Typically, these symptoms are mild to moderate in severity, but in some patients they can be severe. They usually occur within the first few days after stopping treatment, and similar symptoms are much less commonly reported in patients who accidentally miss a dose. Typically, these symptoms are self-limiting and usually go away within 2 weeks, although some people may experience them for longer (2-3 months or more). It is therefore recommended to gradually reduce the dose of escitalopram after discontinuation of treatment over several weeks or months, depending on the patient's needs. Coronary heart disease Due to limited experience with use, caution should be exercised when using the drug in patients with coronary heart disease (CHD). Cases of QT prolongation It has been established that escitalopram causes a dose-dependent prolongation of the QT interval. Cases of QT prolongation and ventricular arrhythmias, including torsade de pointes, have been reported during the postmarketing period, predominantly in female patients with hypokalemia, or with pre-existing QT prolongation or other cardiovascular disease. It is recommended to exercise caution when recommending the drug to patients with severe bradycardia, patients after a recent acute myocardial infarction, or with uncompensated heart failure. Electrolyte disturbances, such as hypokalemia and hypomagnesemia, increase the risk of dangerous arrhythmias, and these conditions should be corrected before escitalopram is prescribed. If the drug is prescribed to patients with persistent heart disease, an ECG should be performed before starting treatment. If signs of cardiac arrhythmia appear during treatment with escitalopram, treatment should be discontinued and an ECG should be performed. Escitalopram does not interact pharmacodynamically or pharmacokinetically with alcohol. However, as with other psychotropic drugs, the simultaneous use of escitalopram and alcohol is not recommended.

Expert advice

The best antidepressant in terms of tolerability
Lowest sexual impact compared to other SSRIs
Lack of response to escitalopram in elderly patients may indicate Alzheimer's disease
In postmenopausal women, escitalopram works better in combination with estrogen [1]
Escitalopram and fluoxetine show similar effects in the treatment of depression. The only difference noted is that escitalopram significantly improves microinflammation in the patient’s body [6].